QuidelOrtho Co. (NASDAQ:QDEL) Stock Position Raised by Yousif Capital Management LLC

Yousif Capital Management LLC increased its holdings in shares of QuidelOrtho Co. (NASDAQ:QDEL) by 11.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 25,216 shares of the company’s stock after buying an additional 2,646 shares during the period. Yousif Capital Management LLC’s holdings in QuidelOrtho were worth $1,123,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of QDEL. Point72 Asset Management L.P. acquired a new position in shares of QuidelOrtho during the third quarter valued at $34,320,000. Rubric Capital Management LP boosted its stake in QuidelOrtho by 15.2% during the 3rd quarter. Rubric Capital Management LP now owns 4,200,000 shares of the company’s stock valued at $191,520,000 after purchasing an additional 554,410 shares during the period. Segall Bryant & Hamill LLC bought a new position in QuidelOrtho in the 3rd quarter worth about $19,565,000. Beaconlight Capital LLC acquired a new stake in shares of QuidelOrtho in the third quarter valued at approximately $18,152,000. Finally, State Street Corp raised its holdings in shares of QuidelOrtho by 16.9% during the third quarter. State Street Corp now owns 1,907,898 shares of the company’s stock valued at $87,000,000 after buying an additional 275,522 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. William Blair restated a “market perform” rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. UBS Group upped their price target on shares of QuidelOrtho from $43.00 to $45.00 and gave the company a “neutral” rating in a report on Thursday. Royal Bank of Canada cut their price objective on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a research report on Thursday. Jefferies Financial Group initiated coverage on QuidelOrtho in a report on Tuesday, December 10th. They issued a “hold” rating and a $43.00 target price on the stock. Finally, Citigroup raised QuidelOrtho from a “neutral” rating to a “buy” rating and upped their target price for the company from $44.00 to $50.00 in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, QuidelOrtho currently has a consensus rating of “Hold” and a consensus target price of $52.71.

QuidelOrtho Trading Up 4.3 %

NASDAQ QDEL opened at $41.65 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.81 and a debt-to-equity ratio of 0.68. QuidelOrtho Co. has a 1-year low of $29.74 and a 1-year high of $49.56. The firm’s fifty day simple moving average is $43.28 and its 200-day simple moving average is $42.35. The company has a market capitalization of $2.80 billion, a PE ratio of -1.49 and a beta of 0.08.

QuidelOrtho (NASDAQ:QDEL) last issued its earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. As a group, sell-side analysts anticipate that QuidelOrtho Co. will post 1.73 earnings per share for the current fiscal year.

Insider Buying and Selling at QuidelOrtho

In other news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the company’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $35.31, for a total transaction of $291,667,061.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brian J. Blaser acquired 6,033 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average cost of $41.42 per share, for a total transaction of $249,886.86. Following the completion of the purchase, the chief executive officer now directly owns 6,033 shares in the company, valued at $249,886.86. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.